MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Core Insights - MaxCyte, Inc. has signed a Strategic Platform License Agreement (SPL) with Anocca AB to utilize its Flow Electroporation technology and ExPERT™ platform for the development of TCR-T cell therapies [1][2] - Anocca AB will gain non-exclusive rights for research, clinical, and commercial applications of MaxCyte's technology, while MaxCyte will receive annual licensing fees and program-related revenue [2] - Anocca has recently achieved GMP compliance certification and a manufacturing license for its cell therapy production facility, with its lead program targeting advanced pancreatic cancer currently in clinical development [3] Company Overview - MaxCyte is focused on cell engineering and aims to advance the discovery, development, and commercialization of next-generation cell therapies [4] - The company offers Flow Electroporation technology and SeQure DX™ gene editing risk assessment services, which facilitate precise and scalable cell engineering [4] - MaxCyte has over 25 years of experience in advancing cell engineering and is committed to shaping the future of medicine [4]